In contrast, nivolumab treatment did not induce any changes in the proportions of T cells and B cells of HD-M; however, the proportion of T cells was significantly increased, and CD19+ B cell levels were significantly decreased in BC-M (Fig. 5C, CH401 vs. CH401 + NIVO). The gene discussed is CD19; the disease is breast cancer.